Cipher CIP-tramadol NDA in second quarter
This article was originally published in Pharmaceutical Approvals Monthly
Cipher plans to submit an NDA for its once-daily, sustained-release tramadol formulation in the second quarter, the firm announces Jan. 26. "Cipher has been advised by the FDA that its existing clinical data package meets the requirements to file an NDA," the company reports. The company adds that it has completed enrollment of its ongoing Phase III trial for the product; results will be available in Q3 '06. Cipher has another application pending: its CIP-isotretinoin product has a May 1 user fee date. The firm saw its first drug approval Jan. 11, with the clearance of the cholesterol-lowering agent Lipofen (fenofibrate) via the 505(b)(2) pathway...
You may also be interested in...
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.